Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCNS2 encodes Potassium voltage-gated channel subfamily S member 2 (Kv9.2), an “electrically silent” alpha subunit that does not form functional potassium channels on its own but instead coassembles with pore-forming subunits such as Kv2.1 and Kv2.2, modifying their activation and inactivation kinetics, voltage dependencies, and expression. This dynamic modulation fine-tunes neuronal excitability and signal transduction, especially in brain regions like the cortex, hippocampus, and cerebellum. Mutations or deletions in KCNS2 have been associated with essential tremor and neurodevelopmental disorders, and expression changes have been linked to neurodegenerative processes. The subunit functions in potassium ion transport but is not itself pore-forming, instead acting as a channel regulator. No direct pharmacological modulators are available or in clinical use for KCNS2, and its status as a disease biomarker or safety issue is theoretical at this stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily S member 2 (KCNS2 (Kv9.2)).